Neurocrine Biosciences (NASDAQ:NBIX) Given New $180.00 Price Target at Robert W. Baird

Neurocrine Biosciences (NASDAQ:NBIX) had its price target upped by Robert W. Baird from $157.00 to $180.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other equities analysts also recently weighed in on NBIX. Oppenheimer upped their target price on Neurocrine Biosciences from $200.00 to $216.00 and gave the company an outperform rating in a report on Thursday, May 2nd. Guggenheim increased their price objective on Neurocrine Biosciences from $164.00 to $170.00 and gave the stock a buy rating in a report on Thursday, May 2nd. Morgan Stanley increased their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an overweight rating in a report on Friday, July 12th. JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $169.00 to $173.00 and gave the stock an overweight rating in a report on Wednesday, July 10th. Finally, UBS Group increased their price objective on Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a buy rating in a report on Tuesday, May 28th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $157.16.

Neurocrine Biosciences Trading Down 0.0 %

NBIX stock traded down $0.01 during mid-day trading on Friday, reaching $153.14. 799,316 shares of the stock traded hands, compared to its average volume of 781,810. Neurocrine Biosciences has a 52-week low of $100.52 and a 52-week high of $157.98. The company has a market cap of $15.41 billion, a P/E ratio of 42.19 and a beta of 0.37. The stock’s fifty day moving average is $139.82 and its 200-day moving average is $138.41.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The business had revenue of $515.30 million during the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. Equities research analysts expect that Neurocrine Biosciences will post 4.22 earnings per share for the current year.

Insider Activity

In other news, Director Stephen A. Sherwin sold 40,000 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the sale, the director now directly owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Ingrid Delaet sold 273 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $140.55, for a total value of $38,370.15. Following the completion of the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,055,108.85. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 80,709 shares of company stock valued at $11,009,150. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NBIX. Vestal Point Capital LP bought a new position in Neurocrine Biosciences in the fourth quarter worth $105,408,000. Los Angeles Capital Management LLC lifted its position in Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after purchasing an additional 364,986 shares during the period. Norges Bank bought a new position in Neurocrine Biosciences in the fourth quarter worth $35,731,000. Vanguard Group Inc. lifted its position in Neurocrine Biosciences by 2.3% in the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after purchasing an additional 220,598 shares during the period. Finally, Iron Triangle Partners LP acquired a new position in Neurocrine Biosciences during the first quarter worth $30,342,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.